Literature DB >> 1654312

Evidence of sex difference in DNA synthesis in hepatocellular carcinoma.

K Tarao1, A Shimizu, M Harada, T Ono, Y Kuni, S Ohkawa, Y Ito, S Tamai, K Iimori, Y Sugimasa.   

Abstract

To clarify sex differences in DNA synthesis in hepatocellular carcinoma (HCC), bromodeoxyuridine labeling indices (BrdU LI) of HCC cells included in tumor biopsy specimens from 12 consecutive male patients and from 5 consecutive female patients all with liver cirrhosis and HCC were examined using an in vitro labeling technique. The mean BrdU LI +/- SE of HCC from male patients (7.7 +/- 0.8%) was significantly (P less than 0.05) higher than that from female patients (4.4 +/- 1.0%). While 7 of the 12 male HCC patients belonged to the high DNA synthesis group (BrdU LI greater than or equal to 7.0%), none of the 5 female HCC patients showed high DNA synthesis (P less than 0.05). We conclude that DNA synthesis in HCC was higher in males than in females.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654312      PMCID: PMC5918578          DOI: 10.1111/j.1349-7006.1991.tb01922.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  24 in total

1.  Influence of sex and sex hormones on development of hepatomas and other hepatic lesions in strain AX C rats ingesting 2-diacetylaminofluorene.

Authors:  H P MORRIS; H I FIRMINGER
Journal:  J Natl Cancer Inst       Date:  1956-02       Impact factor: 13.506

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Increased hepatic androgen receptor expression in female rats during diethylnitrosamine liver carcinogenesis. A possible correlation with liver tumor development.

Authors:  J L Ostrowski; P M Ingleton; J C Underwood; M A Parsons
Journal:  Gastroenterology       Date:  1988-05       Impact factor: 22.682

5.  Estrogen receptors in hepatocellular carcinoma.

Authors:  N Nagasue; A Ito; H Yukaya; Y Ogawa
Journal:  Cancer       Date:  1986-01-01       Impact factor: 6.860

6.  Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection.

Authors:  N Nagasue; Y C Chang; T Hayashi; G Galizia; H Kohno; T Nakamura; H Yukaya
Journal:  Ann Surg       Date:  1989-04       Impact factor: 12.969

7.  Immunohistochemical and ultrastructural localization of epidermal growth factor receptor in human liver and hepatocellular carcinoma tissues.

Authors:  T Fukusato; S Mori; T Kawamoto; S Taniguchi; R Machinami
Journal:  Acta Pathol Jpn       Date:  1990-01

8.  Expression of high- and low-affinity epidermal growth factor receptors in human hepatoma cell lines.

Authors:  M Clementi; A Festa; I Testa; P Bagnarelli; G Devescovi; G Carloni
Journal:  FEBS Lett       Date:  1989-06-05       Impact factor: 4.124

9.  Gut-derived endotoxin elicits hepatotrophic factor secretion for liver regeneration.

Authors:  R P Cornell
Journal:  Am J Physiol       Date:  1985-11

10.  Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure.

Authors:  H Tsubouchi; S Hirono; E Gohda; H Nakayama; K Takahashi; O Sakiyama; H Miyazaki; J Sugihara; E Tomita; Y Muto
Journal:  Hepatology       Date:  1989-06       Impact factor: 17.425

View more
  2 in total

Review 1.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

2.  Sex-determination gene SRY potentially associates with poor prognosis but not sex bias in hepatocellular carcinoma.

Authors:  Tong-Chun Xue; Lan Zhang; Zheng-Gang Ren; Rong-Xin Chen; Jie-Feng Cui; Ning-Ling Ge; Sheng-Long Ye
Journal:  Dig Dis Sci       Date:  2014-10-02       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.